Professor Lorna Harries is a Professor of Molecular Genetics at the University of Exeter College of Medicine and Health, where she leads the RNA-Mediated Disease Mechanisms Group. She earned her PhD in Genetics from University College London in 1994 and has since established herself as a leading expert in RNA biology, gene regulation, and the molecular mechanisms of ageing. Her research focuses on alternative messenger RNA processing, non-coding RNAs, and epigenetic regulation in ageing and chronic disease. Professor Harries is also the co-founder, director, and chief scientific officer of SENISCA, a senotherapeutics biotechnology company translating her team’s discoveries into anti-ageing therapeutics. Her group was the first to identify dysregulation of alternative splicing as a druggable hallmark of ageing, marking a major advancement in the field. In addition to her molecular research, Professor Harries is deeply committed to engaged, participatory science. She has led a Wellcome Trust-funded study involving local students to examine human exposure to endocrine-disrupting chemicals, producing high-impact findings that influenced public awareness, media discourse, and policy discussions around single-use plastics. She holds a Fellowship of the Higher Education Academy and continues to bridge fundamental science with societal impact through innovation and collaboration. https://experts.exeter.ac.uk/1873-lorna-harries.
Professor Lorna Harries is a Professor of Molecular Genetics at the University of Exeter College of Medicine and Health, where she leads the RNA-Mediated Disease Mechanisms Group. She earned her PhD in Genetics from University College London in 1994 and has since established herself as a leading expert in RNA biology, gene regulation, and the molecular mechanisms of ageing. Her research focuses on alternative messenger RNA processing, non-coding RNAs, and epigenetic regulation in ageing and chronic disease. Professor Harries is also the co-founder, director, and chief scientific officer of SENISCA, a senotherapeutics biotechnology company translating her team’s discoveries into anti-ageing therapeutics. Her group was the first to identify dysregulation of alternative splicing as a druggable hallmark of ageing, marking a major advancement in the field. In addition to her molecular research, Professor Harries is deeply committed to engaged, participatory science. She has led a Wellcome Trust-funded study involving local students to examine human exposure to endocrine-disrupting chemicals, producing high-impact findings that influenced public awareness, media discourse, and policy discussions around single-use plastics. She holds a Fellowship of the Higher Education Academy and continues to bridge fundamental science with societal impact through innovation and collaboration. https://experts.exeter.ac.uk/1873-lorna-harries.